Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-β1 and type IV collagen in diabetic vasculopathy

Journal of Hypertension

Volumn 16, Issue 11, 1998, Pages 1603-1609

  Rumble, Jonathan R ^a   Gilbert, Richard E ^a   Cox, Alison ^a   Wu, Leonard ^a   Cooper, Mark E ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b HEIDELBERG REPATRIATION HOSPITAL   (Australia)

Author keywords

Angiotensin converting enzyme inhibition; Angiotensin II; Diabetes mellitus; Mesenteric arteries; Transforming growth factor

Indexed keywords

COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA; RAMIPRIL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; IMMUNOHISTOCHEMISTRY; MALE; MESENTERY BLOOD VESSEL; NONHUMAN; NORTHERN BLOTTING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

EID: 0031766033     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816110-00006     Document Type: Article

References (40)

1. Clark CMJ, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995; 332:1210-1217.
2. Williamson JR, Tilton RG, Chang K, Kilo C. Basement membrane abnormalities in diabetes mellitus: relationship to clinical microangiopathy. Diabetes Metab Rev 1988; 4:339-370.
3. Cooper ME, Rumble J, Komers R, Du HC, Jandeleit K, Chou ST: Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 1994; 43:1221-1228.
4. Vranes D, Cooper ME, Dilley RJ. Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies. J Vasc Res 1995; 32:183-189.
5. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992; 42:46-55.
6. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, et al. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245:186-188.
7. Farhy RD, Carretero OA, Ho KL, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993; 72:1202-1210.
8. Rumble JR, Doyle AE, Cooper ME. Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension and diabetes. Am J Hypertens 1995; 8:53-57.
9. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in diabetic rat. Kidney Int 1989; 36:536-536.
10. Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7 (suppl):84s-92s.
11. Lewis EJ, Hunsicker LG, Bain RP, Ronde RD, for the Collaborative Study Group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
12. Owens GK, Geisterfer AA, Yang YW, Komonya A. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol 1988; 107:771-780.
13. Border WA, Noble NA. Mechanisms of disease: transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331:1286-1292.
14. Striker GE, Peten EP, Carome MA, Pesce CM, Schmidt K, Yang C-W, et al. The kidney disease of diabetes mellitus (KDDM): a cell and molecular biology approach. Diabetes Metab Rev 1993; 9:37-56.
15. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993; 90:1814-1818.
16. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen L, Jerums G, Cooper ME. Expression of transforming growth factor-β, and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of angiotensin converting enzyme inhibition. Diabetes 1998; 47:414-422.
17. Yokoyama H, Deckert T. Central role of TGF-beta in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Diabet Med 1996; 13:313-320.
18. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90:456-461.
19. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994; 93:536-542.
20. Bunag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 1973; 34:279-282.
21. Schmidt FH. Enzymatic determination of glucose and fructose simultaneously. Klin Wochenschr 1961; 39:1244-1247.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159.
23. Floege J, Alpers CE, Burns MW, Pritzl P, Gordon K, Couser WG, et al. Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. Lab Invest 1992; 66:485-497.
24. Masson P. Trichrome stainings and their preliminary technique. J Tech Methods 1929; 2:75-90.
25. Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Jasik M, et al. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin Invest 1997; 99:1016-1027.
26. Snedecor GW, Cochran WG. Statistical methods, 7th ed. Ames, Iowa: Iowa State University Press; 1980:228-236.
27. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977; 57:313-370.
28. Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharmacol 1993; 22 (suppl 5):S1-S9.
29. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62:749-756.
30. Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A, et al. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991; 9:17-22.
31. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68:450-456.
32. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. J Clin Invest 1994; 94:978-984.
33. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93:2431-2437.
34. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265:F477-F486.
35. Brownlee MA, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:131-138.
36. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994; 91:9436-9440.
37. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44:1139-1146.
38. Erdos EG. Conversion of angiotensin I to angiotensin II. Am J Med 1976; 60:749-759.
39. Rumble JR, Komers R, Cooper ME. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens 1996; 14:601-607.
40. Allen TJ, Cao Z, Yousef S, Hulthen UL, Cooper ME. The role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural aspects. Diabetes 1997; 46:1612-1618.